Effect of topically applied resveratrol on cutaneous herpes simplex virus infections in hairless mice

Antiviral Research

Volumn 61, Issue 1, 2004, Pages 19-26

  Docherty, John J ^a   Smith, Jennifer S ^a   Fu, Ming Ming ^a   Stoner, Terri ^a   Booth, Tristan ^b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

HSV; In vivo; Resveratrol

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; BEHENYL ALCOHOL; FATTY ALCOHOL; RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREAM; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; EPIDERMIS; GROWTH, DEVELOPMENT AND AGING; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES VIRUS INFECTION; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; MOUSE STRAIN; NONHUMAN; NUDE MOUSE; OINTMENT; PRIORITY JOURNAL; SKIN ABRASION; SKIN DEFECT; TIME; TOPICAL DRUG ADMINISTRATION; VIRAL SKIN DISEASE;

ANIMALIA; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS; VITACEAE;

EID: 0345547465     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2003.07.001     Document Type: Article

References (39)

1. Belguendouz L., Fremont L., Gozzelino M.T. Interaction of transresveratrol with plasma lipoproteins. Biochem. Pharmacol. 55:1998;811-816.
2. Bourne N., Bravo F.J., Ashton W.T., Meurer L.C., Tolman R.L., Karkas J.D., Stanberry L.R. Assessment of a selective inhibitor of herpes simplex virus thymidine kinase (L-653, 180) as therapy for experimental recurrent genital herpes. Antimicrob. Agents Chemother. 36:1992;2020-2024.
3. Cai Y.J., Fang J.G., Ma L.P., Yang L., Liu Z.L. Inhibition of free radical-induced peroxidation of rat liver microsomes by resveratrol and its analogues. Biochim. Biophys. Acta. 1637:2003;31-38.
4. Crute J.J., Grygon C.A., Hargrave K.D., Simoneau B., Faucher A.-M., Bolger G., Kibler P., Liuzzi M., Cordingley M.G. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med. 8:2002;386-391.
5. Delmas D., Passilly-Degrace P., Jannin B., Malki M.C., Latruffe N. Resveratrol, a chemopreventive agent, disrupts the cell cycle control of human SV480 colorectal tumor cells. Int. J. Mol. Med. 10:2002;193-199.
6. Docherty J.J., Fu M.M.H., Stiffler B.S., Limperos R.J., Pokabla C.M., DeLucia A.L. Resveratrol inhibition of herpes simplex virus replication. Antivir. Res. 43:1999;145-155.
7. Docherty J.J., Fu M.M.H., Tsai M. Resveratrol selectively inhibits Neisseria gonorrhoeae and Neisseria meningitidis. J. Antimicrob. Chemother. 47:2001;243-244.
8. Elion G.B., Furman P.A., Fyfe J.A., deMiranda P., Beauchamp L., Schaeffer H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. U.S.A. 74:1977;5716-5720.
9. Field H.J. Herpes simplex virus antiviral drug resistance-current trends and future prospects. J. Clin. Virol. 21:2001;261-269.
10. Flores-Aguilar M., Besen G., Vuong C., Tatebayashi M., Munguia D., Gangan P., Wiley C.A., Freeman W.R. Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015. J. Infect. Dis. 175:1997;1308-1316.
11. Fontecave M., Lepoivre M., Elleingard E., Gerez C., Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 421:1998;277-279.
12. Fremont L. Biological effects of resveratrol. Life Sci. 66:2000;663-673.
13. Fremont L., Belguendouz L., Delpol S. Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids. Life Sci. 64:1999;2511-2521.
14. Fukuhara K., Miyata N. Resveratrol as a new type of DNA-cleaving agent. Bioorg. Med. Chem. Lett. 8:1999;3187-3192.
15. Goldberg D.M., Hahn S.E., Parkes J.G. Beyond alcohol: beverage consumption and cardiovascular mortality. Clin. Chem. Acta. 237:1995;155-187.
16. Goldstein D.J., Weller S.K. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62:1988;196-205.
17. Holian O., Walter R.J. Resveratrol inhibits the proliferation of normal human keratinocytes in vitro. J. Cell. Biochem. Suppl. 36:2001;55-62.
18. Hossain A., Holt T., Ciacci-Zanella J., Jones C. Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection. J. Gen. Virol. 78:1997;3341-3348.
19. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W.W., Fong H.H.S., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 275:1997;218-220.
20. Jayatilake G.S., Jayasuriya H., Lee E.-S., Koonchanok N.M., Geahlen R.L., Ashendel C.L., McLaughlin J.L., Chang C.-J. Kinase inhibitors from Polygonum cuspidatum. J. Nat. Prod. 56:1993;1805-1810.
21. Jeandet P., Bessis R., Sbaghi R., Meunier M. Production of the phytoalexin resveratrol by grapes as a response to botrytis attack under natural conditions. J. Phytopathol. 143:1995;135-139.
22. Kleymann G., Fischer R., Betz U.A.K., Hendrix M., Bender W., Schneider U., Handke G., Eckenberg P., Hewlett G., Pevzner V., Baumeister J., Weber O., Henninger K., Keldenich J., Jensen A., Kolb J., Bach U., Papp A., Maben J., Frappa I., Haebich D., Lockhoff O., Rubsamen-Waigmann H. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat. Med. 8:2002;392-398.
23. Knopf K.W. Properties of herpes simplex virus DNA polymerase and characterization of its associated exonuclease activity. Eur. J. Biochem. 98:1979;231-244.
24. McKeough M.B., Spruance S.L. Comparison of new topical treatments for herpes, labialis: efficacy of penciclovir cream, acyclovir cream, an n-docosanol cream against experimental cutaneous herpes simplex virus type 1 infection. Arch. Dermatol. 137:2001;1153-1158.
25. Naderali E.K., Doyle P.J., Williams G. Resveratrol induces vasorelaxation of mesenteric and uterine arteries from female guinea pigs. Clin. Sci. 98:2000;537-543.
26. Narayanan B.A., Narayanan N.K., Re G.G., Nixon D.W. Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int. J. Cancer. 104:2003;204-212.
27. Norbury C., Nurse P. Animal cell cycles and their controls. Ann. Rev. Biochem. 61:1992;441-470.
28. Parris D.S., Harrington J.E. Herpes simplex virus variants resistant to high concentrations of acyclovir exist in clinical isolates. Antimicrob. Agents Chemother. 22:1982;71-77.
29. Pope L.E., Marcelletti J.F., Katz L.R., Lin J.Y., Katz D.H., Parish M.L., Spear P.G. The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Antivir. Res. 40:1998;85-94.
30. Ragione F.D., Cucciolla V., Borriello A., Pietra V.D., Racioppi L., Soldati G., Manna C., Galletti P., Zappia V. Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem. Biophys. Res. Commun. 250:1998;53-58.
31. Sacks S.L., Thisted R.A., Jones T.M., Barbarash R.A., Mikolich D.J., Ruoff G.E., Jorizzo J.L., Gunnill L.B., Katz D.H., Khalil M.H., Morrow P.R., Yakatan G.J., Pope L.E., Berg J.E. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: a multicenter, randomized, placebo-controlled trial. J. Am. Acad. Dermatol. 45:2001;222-230.
32. Schang L.M., Phillips J., Schaffer P.A. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription. J. Virol. 72:1998;5626-5637.
33. Smith C.C., Peng T., Kulka M., Aurelian L. The PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for immediate-early gene expression and virus growth. J. Virol. 72:1998;9131-9141.
34. Soleas G.J., Diamandis E.P., Goldberg D.M. Wine as a biological fluid: history, production, and role in disease prevention. J. Clin. Lab. Anal. 11:1997;287-313.
35. Stewart J.R., Ward N.E., Ioannides C.G., O'Brian C.A. Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism. Biochemistry. 38:1999;13244-13251.
36. Stivala L.A., Savio M., Carafoli F., Perucca P., Bianchi L., Maga G., Forti L., Pagnoni U.M., Albini A., Prosperi E., Vannini V. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J. Biol. Chem. 276:2001;22586-22594.
37. Sun N.J., Woo S.H., Cassady J.M., Snapka R.M. DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. J. Nat. Prod. 61:1998;362-366.
38. Waxman L., Darke P.L. The herpesvirus proteases as targets for antiviral chemotherapy. Antivir. Chem. Chemother. 11:2000;1-22.
39. Whitley, R.J., Gnann, J.W., 1993. The epidemiology and clinical manifestations of herpes simplex virus infections. In: Roizman, B., Whitley, R.J., Lopez, C., (Eds.), The Human Herpesviruses. Lippincott-Raven, Philadelphia, pp. 69-105.